Basal cell carcinoma - Basozelulen Kartzinoma
☆ AI Dermatology — Free Service
Alemaniako Stiftung Warentest-en 2022ko emaitzetan, ModelDerm-ekin kontsumitzaileen gogobetetasuna apur bat txikiagoa izan zen ordaindutako telemedikuntzako kontsultekin baino.
Alemaniako Stiftung Warentest-en 2022ko emaitzetan, ModelDerm-ekin kontsumitzaileen gogobetetasuna apur bat txikiagoa izan zen ordaindutako telemedikuntzako kontsultekin baino.
Adineko pertsonen sudurreko larruazalean agertzen diren ultzeratutako lesioak sarritan Basozelulen kartzinoma (Basal cell carcinoma) gisa diagnostikatzen dira. Sudurra azaleko minbizi mota honen ohiko agerraldia da.
Basozelulen Kartzinoma (Basal cell carcinoma) ertz irregularak eta ulzerak ager daitezke.
Basozelulen kartzinoma (Basal cell carcinoma) garatxoarekin nahastu daiteke.
relevance score : -100.0%
ReferencesBasal cell carcinoma (BCC) azaleko minbizi mota ohikoena da. Eguzki-argirako esposizioa da kausa nagusia. BCC kasu ia guztiek analisi molekularrean Hedgehog-en seinaleztapena erakusten dute. Tratamendu desberdinak eskuragarri daude eta hauek errepikatzeko arriskuaren, ehunen kontserbazioaren garrantziaren, pazientearen hobespenaren eta gaixotasunaren neurriaren arabera hautatzen dira.
Basal cell carcinoma (BCC) is the most common malignancy. Exposure to sunlight is the most important risk factor. Most, if not all, cases of BCC demonstrate overactive Hedgehog signaling. A variety of treatment modalities exist and are selected based on recurrence risk, importance of tissue preservation, patient preference, and extent of disease.
Basal cell carcinoma (BCC) is the most common malignancy. Exposure to sunlight is the most important risk factor. Most, if not all, cases of BCC demonstrate overactive Hedgehog signaling. A variety of treatment modalities exist and are selected based on recurrence risk, importance of tissue preservation, patient preference, and extent of disease.
Basal cell carcinomas larruazaleko minbizi mota ohikoena da 50 urtetik gorako larruazal zuriko helduen artean. Haien kopuruak gora egiten ari dira mundu osoan, batez ere eguzki-argiaren eraginpean egoteagatik. Zenbait baldintza genetikoek adin txikiagotan minbizi horiek garatzeko joera izan dezakete. Basal cell carcinomas-en larritasuna aldatu egiten da: erraz trata daitezkeen azaleko edo nodular lesioetatik hasi eta mediku talde espezializatuetan eztabaidatu behar diren zabalagoetarako. Pronostikoa minbizia itzultzeko probabilitatearen edo inguruko ehunak kaltetzeko duen gaitasunaren araberakoa da. Kirurgia tratamendu estandarra da kasu gehienetarako, kentzea zehatza eta errepikatzeko aukera baxuak bermatuz. Metodo gutxiagorekin inbaditzaileek modu eraginkorrean trata ditzakete azaleko lesioak.
Basal cell carcinomas are the most frequent skin cancers in the fair-skinned adult population over 50 years of age. Their incidence is increasing throughout the world. Ultraviolet (UV) exposure is the major carcinogenic factor. Some genodermatosis can predispose to formation of basal cell carcinomas at an earlier age. Basal cell carcinomas are heterogeneous, from superficial or nodular lesions of good prognosis to very extensive difficult-to-treat lesions that must be discussed in multidisciplinary committees. The prognosis is linked to the risk of recurrence of basal cell carcinoma or its local destructive capacity. The standard treatment for most basal cell carcinomas is surgery, as it allows excision margin control and shows a low risk of recurrence. Superficial lesions can be treated by non-surgical methods with significant efficacy.
Basal cell carcinomas are the most frequent skin cancers in the fair-skinned adult population over 50 years of age. Their incidence is increasing throughout the world. Ultraviolet (UV) exposure is the major carcinogenic factor. Some genodermatosis can predispose to formation of basal cell carcinomas at an earlier age. Basal cell carcinomas are heterogeneous, from superficial or nodular lesions of good prognosis to very extensive difficult-to-treat lesions that must be discussed in multidisciplinary committees. The prognosis is linked to the risk of recurrence of basal cell carcinoma or its local destructive capacity. The standard treatment for most basal cell carcinomas is surgery, as it allows excision margin control and shows a low risk of recurrence. Superficial lesions can be treated by non-surgical methods with significant efficacy.
BCCren tratamendu nagusia kirurgia da. Arrisku handiko edo errepikakorra den BCCrako, bereziki eremu kritikoetan, mikrografikoki kontrolatutako kirurgia gomendatzen da. Arrisku baxuko azaleko BCC duten pazienteek tratamendu topikoak edo metodo suntsitzaileak kontuan hartu ditzakete. Terapia fotodinamikoa ondo funtzionatzen du azaleko eta arrisku baxuko BCC nodularretarako. BCC lokalean aurreratu edo metastatikorako, Hedgehog inhibitzaileak (vismodegib or sonidegib) gomendatzen dira. Hedgehog inhibitzaileekiko gaixotasunaren progresioa edo intolerantzia badago, anti‑PD1 antibody (cemiplimab) immunoterapia kontuan hartu daiteke. Erradioterapia aukera ona da ebakuntza ezin duten pazienteentzat, batez ere adineko pazienteentzat. Elektrokimioterapia ere kontuan hartu daiteke kirurgia edo erradioterapia aukera bat ez badago.
The primary treatment for BCC is surgery. For high-risk or recurring BCC, especially in critical areas, micrographically controlled surgery is recommended. Patients with low-risk superficial BCC might consider topical treatments or destructive methods. Photodynamic therapy works well for superficial and low-risk nodular BCCs. For locally advanced or metastatic BCC, Hedgehog inhibitors (vismodegib, sonidegib) are recommended. If there's disease progression or intolerance to Hedgehog inhibitors, immunotherapy with anti-PD1 antibody (cemiplimab) can be considered. Radiotherapy is a good option for patients who can't have surgery, especially older patients. Electrochemotherapy could be considered if surgery or radiotherapy isn't an option.
The primary treatment for BCC is surgery. For high-risk or recurring BCC, especially in critical areas, micrographically controlled surgery is recommended. Patients with low-risk superficial BCC might consider topical treatments or destructive methods. Photodynamic therapy works well for superficial and low-risk nodular BCCs. For locally advanced or metastatic BCC, Hedgehog inhibitors (vismodegib, sonidegib) are recommended. If there's disease progression or intolerance to Hedgehog inhibitors, immunotherapy with anti-PD1 antibody (cemiplimab) can be considered. Radiotherapy is a good option for patients who can't have surgery, especially older patients. Electrochemotherapy could be considered if surgery or radiotherapy isn't an option.
Arrisku‑faktoreak argi ultramorearen esposizioa, erradioterapia, artsenikoarekiko epe luzeko esposizioa eta immunitate‑sistemaren funtzio eskasa (adibidez, organoen transplantea) dira. Haurtzaroan UV argiaren esposizioa bereziki kaltegarria da.
Biopsiaren bidez diagnostikatu ondoren, tratamendua normalean kentze kirurgikoa da. Minbizia txikia bada, ebakidura sinple baten bidez tratatu daiteke; minbizia txikia ez bada, Mohs‑en kirurgia gomendatzen da oro har.
Baso‑zelulen kartzinomak mundu osoko minbizi guztien gutxienez %32a hartzen du. Melanoma ez den larruazaleko minbizietatik, %80 inguru zelula basaletako minbiziak dira. Estatu Batuetan, gizonezko zurien %35 inguru eta emakume zurien %25 inguru zelula baso‑zelulen kartzinomak jasaten dituzte bizitzako uneren batean.
○ Diagnostikoa eta Tratamendua
#Dermoscopy
#Skin biopsy
#Mohs surgery